GAG-SPECIFIC CYTOTOXIC RESPONSES TO HIV TYPE-1 ARE ASSOCIATED WITH A DECREASED RISK OF PROGRESSION TO AIDS-RELATED COMPLEX OR AIDS

被引:146
作者
RIVIERE, Y
MCCHESNEY, MB
PORROT, F
TANNEAUSALVADORI, F
SANSONETTI, P
LOPEZ, O
PIALOUX, G
FEUILLIE, V
MOLLEREAU, M
CHAMARET, S
TEKAIA, F
MONTAGNIER, L
机构
[1] INST PASTEUR, DEPT RETROVIRUS, CNRS, URA 1157, F-75015 PARIS, FRANCE
[2] INST PASTEUR, DEPT MED, F-75015 PARIS, FRANCE
[3] HOP LA PITIE SALPETRIERE, CTR TRANSFUS SANGUINE, F-75013 PARIS, FRANCE
[4] INST PASTEUR, SERV INFORMAT SCI, F-75015 PARIS, FRANCE
关键词
D O I
10.1089/aid.1995.11.903
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The duration of human immunodeficiency virus (HIV-1) infection prior to the development of AIDS is variable, and for most patients the exact time of infection is not known, A group of 38 HIV-1-infected subjects was tested while asymptomatic for comparative cytotoxic lymphocyte responses to the Gag and envelope antigens of HIV-1. Twenty of the 38 patients had no detectable primary cytotoxic T lymphocyte (CTL) response to Gag, and this was associated with a relative risk of 1.89 for progression to ARC or AIDS during the subsequent 3 to 40 months of observation when compared with patients who had Gag-specific CTL activity at the beginning of the observation period, In contrast, no significant association was observed between envelope-specific cytotoxic activity and disease progression, Other patient characteristics, including CD4(+) T lymphocyte counts and antibody levels to the p24(gag) protein, measured at the start of observation, did not correlate with disease progression during the observation period. This suggests that the anti-Gag CTL response may be protective during HIV-1 infection.
引用
收藏
页码:903 / 907
页数:5
相关论文
共 26 条
[1]   THE IMMUNOLOGICAL PRINCIPLES OF VACCINATION [J].
ADA, GL .
LANCET, 1990, 335 (8688) :523-526
[2]  
[Anonymous], 1987, Morbidity and Mortality Weekly Report, V36, P1
[3]  
BURNET FM, 1968, LANCET, V2, P610
[4]   HIV-SPECIFIC CD8+ T-CELL IMMUNE-RESPONSES AND VIRAL REPLICATION [J].
BUSEYNE, F ;
RIVIERE, Y .
AIDS, 1993, 7 :S81-S85
[5]   VIROLOGICAL AND IMMUNOLOGICAL CHARACTERIZATION OF LONG-TERM SURVIVORS OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION [J].
CAO, YZ ;
QIN, LM ;
ZHANG, LQ ;
SAFRIT, J ;
HO, DD .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (04) :201-208
[6]  
Dixon W. J., 1990, BMDP STATISTICAL SOF
[7]   ASSOCIATION OF ANTIBODY TO HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 CORE PROTEIN (P24), CD4+ LYMPHOCYTE NUMBER, AND AIDS-FREE TIME [J].
FARZADEGAN, H ;
CHMIEL, JS ;
ODAKA, N ;
WARD, L ;
POGGENSEE, L ;
SAAH, A ;
PHAIR, JP .
JOURNAL OF INFECTIOUS DISEASES, 1992, 166 (06) :1217-1222
[8]   THE INFLUENCE OF LYMPHOCYTE COUNTS AND DISEASE PROGRESSION ON CIRCULATING AND INDUCIBLE ANTI-HIV-1 CYTOTOXIC T-CELL ACTIVITY IN HIV-1-INFECTED SUBJECTS [J].
GRANT, MD ;
SMAILL, FM ;
SINGAL, DP ;
ROSENTHAL, KL .
AIDS, 1992, 6 (10) :1085-1094
[9]  
HO HN, 1993, J IMMUNOL, V150, P3070
[10]  
KOUP RA, 1989, BLOOD, V73, P1909